TY - JOUR
T1 - Patients with inflammatory bowel disease are not at increased risk of covid-19
T2 - a large multinational cohort study
AU - Allocca, Mariangela
AU - Chaparro, María
AU - Gonzalez, Haidee Aleman
AU - Bosca-Watts, Marta Maia
AU - Palmela, Carolina
AU - D’amico, Ferdinando
AU - Zacharopoulou, Eirini
AU - Kopylov, Uri
AU - Ellul, Pierre
AU - Bamias, Giorgos
AU - Ntelis, Vassilios
AU - Lahat, Adi
AU - Mantzaris, Gerassimos J.
AU - Papaconstantinou, Ioannis
AU - Katsanos, Konstantinos
AU - Uspenskaya, Yulia
AU - Christodoulou, Dimitrios
AU - Horin, Shomron Ben
AU - Peyrin-Biroulet, Laurent
AU - Torres, Joanna
AU - Sebastian, Shaji
AU - Gisbert, Javier P.
AU - Danese, Silvio
AU - Fiorino, Gionata
N1 - Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/11
Y1 - 2020/11
N2 - The impact of COVID-19 on inflammatory bowel disease (IBD) patients under pharmacological immunosuppression is still not clearly understood. We investigated the incidence of COVID-19 and the impact of immunosuppression and containment measures on the risk of SARS-CoV-2 infection in a large IBD cohort, from a multicenter cohort from 21st of February to 30th of June, 2020. Ninety-seven patients with IBD (43 UC, 53 CD, one unclassified IBD) and concomitant COVID-19 over a total of 23,879 patients with IBD were enrolled in the study. The cumulative incidence of SARS-CoV-2 infection in patients with IBD vs. the general population was 0.406% and 0.402% cases, respectively. Twenty-three patients (24%) were hospitalized, 21 (22%) had pneumonia, four (4%) were admitted to the Intensive Care Unit, and one patient died. Lethality in our cohort was 1% compared to 9% in the general population. At multivariable analysis, age > 65 years was associated with increased risk of pneumonia and hospitalization (OR 11.6, 95% CI 2.18–62.60; OR 5.1, 95% CI 1.10–23.86, respectively), treatment with corticosteroids increased the risk of hospitalization (OR 7.6, 95% CI 1.48–40.05), whereas monoclonal antibodies were associated with reduced risk of pneumonia and hospitalization (OR 0.1, 95% CI 0.04–0.52; OR 0.3, 95% CI 0.10–0.90, respectively). The risk of COVID-19 in patients with IBD is similar to the general population. National lockdown was effective in preventing infection in our cohort. Advanced age and treatment with corticosteroids impacted negatively on the outcome of COVID-19, whereas monoclonal antibodies did not seem to have a detrimental effect.
AB - The impact of COVID-19 on inflammatory bowel disease (IBD) patients under pharmacological immunosuppression is still not clearly understood. We investigated the incidence of COVID-19 and the impact of immunosuppression and containment measures on the risk of SARS-CoV-2 infection in a large IBD cohort, from a multicenter cohort from 21st of February to 30th of June, 2020. Ninety-seven patients with IBD (43 UC, 53 CD, one unclassified IBD) and concomitant COVID-19 over a total of 23,879 patients with IBD were enrolled in the study. The cumulative incidence of SARS-CoV-2 infection in patients with IBD vs. the general population was 0.406% and 0.402% cases, respectively. Twenty-three patients (24%) were hospitalized, 21 (22%) had pneumonia, four (4%) were admitted to the Intensive Care Unit, and one patient died. Lethality in our cohort was 1% compared to 9% in the general population. At multivariable analysis, age > 65 years was associated with increased risk of pneumonia and hospitalization (OR 11.6, 95% CI 2.18–62.60; OR 5.1, 95% CI 1.10–23.86, respectively), treatment with corticosteroids increased the risk of hospitalization (OR 7.6, 95% CI 1.48–40.05), whereas monoclonal antibodies were associated with reduced risk of pneumonia and hospitalization (OR 0.1, 95% CI 0.04–0.52; OR 0.3, 95% CI 0.10–0.90, respectively). The risk of COVID-19 in patients with IBD is similar to the general population. National lockdown was effective in preventing infection in our cohort. Advanced age and treatment with corticosteroids impacted negatively on the outcome of COVID-19, whereas monoclonal antibodies did not seem to have a detrimental effect.
KW - COVID-19
KW - Drugs
KW - Immunosuppression
KW - Inflammatory bowel disease
UR - http://www.scopus.com/inward/record.url?scp=85101146593&partnerID=8YFLogxK
U2 - 10.3390/jcm9113533
DO - 10.3390/jcm9113533
M3 - Article
C2 - 33142843
AN - SCOPUS:85101146593
SN - 2077-0383
VL - 9
SP - 1
EP - 10
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
IS - 11
M1 - 3533
ER -
